Fosun Pharma (600196.SH) announced that its wholly-owned subsidiary, Fosun Pharma Industrial Development Co., Ltd., has received approval from the National Medical Products Administration (NMPA) to conduct clinical trials of Fumining (generic name: luvometinib tablets) in combination with anlotinib for patients with advanced non-small cell lung cancer. Fosun Pharma Industrial Development plans to conduct Phase II clinical trials for this drug within China. The drug is a selective MEK1/2 inhibitor that has already been launched in China and approved for two indications. Additionally, marketing applications for two further indications have been accepted by the NMPA and included in the priority review program. According to the latest data from IQVIA MIDAS, global sales of MEK1/2 selective inhibitors reached approximately $2.068 billion in 2024. However, before this drug can be marketed for the newly added indication in China, a series of clinical studies must be conducted and approved by the national drug regulatory authorities. Drug R&D involves certain risks; investors are advised to be aware of these investment risks.